Rafael Cavalcante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10989042/publications.pdf

Version: 2024-02-01

43 papers 1,471 citations

361413 20 h-index 315739 38 g-index

44 all docs

44 docs citations

times ranked

44

2178 citing authors

#	Article	IF	CITATIONS
1	Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. JACC: Cardiovascular Interventions, 2020, 13, 2251-2262.	2.9	70
2	Percutaneous endovascular delivery of calcium chloride to the intact porcine carotid artery: A novel animal model of arterial calcification. Catheterization and Cardiovascular Interventions, 2020, 96, E484-E492.	1.7	3
3	Application of the MADS classification system in a "mega mammoth―stent trial: Feasibility and preliminary clinical implications. Catheterization and Cardiovascular Interventions, 2019, 93, 57-63.	1.7	5
4	Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study. EuroIntervention, 2019, 15, e547-e550.	3.2	16
5	Determinants of success and hemodynamic impact of balloon postdilatation of selfâ€expanding transcatheter aortic valves. Catheterization and Cardiovascular Interventions, 2018, 92, 945-953.	1.7	2
6	<scp>H</scp> emodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model. Catheterization and Cardiovascular Interventions, 2018, 91, 1084-1091.	1.7	5
7	Coronary calcification as a mechanism of plaque/media shrinkage in vessels treated with bioresorbable vascular scaffold: A multimodality intracoronary imaging study. Atherosclerosis, 2018, 269, 6-13.	0.8	10
8	Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease. Journal of Cardiovascular Medicine, 2018, 19, 554-563.	1.5	9
9	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. Journal of the American College of Cardiology, 2018, 71, 2756-2769.	2.8	92
10	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease. JACC: Cardiovascular Interventions, 2018, 11, 1234-1243.	2.9	58
11	A simplified and reproducible method to size the mitral annulus: implications for transcatheter mitral valve replacement. European Heart Journal Cardiovascular Imaging, 2017, 18, jew132.	1.2	17
12	Predictors of longâ€term outcomes after bypass grafting versus drugâ€eluting stent implantation for left main or multivessel coronary artery disease. Catheterization and Cardiovascular Interventions, 2017, 90, 177-185.	1.7	7
13	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. Catheterization and Cardiovascular Interventions, 2017, 89, 679-689.	1.7	17
14	Outcomes of Coronary Artery Bypass Graft Surgery Versus Drugâ€Eluting Stents in Older Adults. Journal of the American Geriatrics Society, 2017, 65, 625-630.	2.6	11
15	Single or dual antiplatelet therapy after PCI. Nature Reviews Cardiology, 2017, 14, 294-303.	13.7	35
16	Angiographic assessment of aortic regurgitation by videoâ€densitometry in the setting of TAVI: Echocardiographic and clinical correlates. Catheterization and Cardiovascular Interventions, 2017, 90, 650-659.	1.7	27
17	Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. Heart, 2017, 103, 428-433.	2.9	19
18	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	31

#	Article	IF	Citations
19	Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non–ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2017, 120, 380-386.	1.6	48
20	Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials. European Heart Journal, 2017, 38, 1969-1977.	2.2	76
21	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2017, 38, 2559-2566.	2.2	42
22	Prevalence, predictors, and prognostic implications of residual impairment of functional capacity after transcatheter aortic valve implantation. Clinical Research in Cardiology, 2017, 106, 752-759.	3.3	17
23	Coronary artery bypass graft surgery versus drug-eluting stent implantation for high-surgical-risk patients with left main or multivessel coronary artery disease. European Journal of Cardio-thoracic Surgery, 2017, 51, 943-949.	1.4	2
24	Reply. Journal of the American College of Cardiology, 2017, 69, 117-118.	2.8	0
25	Detecting Periprocedural MyocardialÂInfarction in Contemporary Percutaneous Coronary Intervention Trials. JACC: Cardiovascular Interventions, 2017, 10, 658-666.	2.9	8
26	Serial Assessment of Tissue Precursors andÂProgression of Coronary Calcification Analyzed by Fusion of IVUS and OCT. JACC: Cardiovascular Imaging, 2017, 10, 1151-1161.	5.3	31
27	Comparative assessment of "plaque/media―change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study. International Journal of Cardiovascular Imaging, 2017, 33, 441-449.	1.5	3
28	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	2.2	244
29	Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1415-1424.	2.9	95
30	Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model. International Journal of Cardiology, 2017, 227, 467-473.	1.7	13
31	Impact of Multivessel Coronary Artery Disease With Versus Without Left Main Coronary Artery Disease on Long-Term Mortality After Coronary Bypass Grafting Versus Drug-Eluting Stent Implantation. American Journal of Cardiology, 2017, 119, 225-230.	1.6	11
32	Non-invasive Heart Team assessment of multivessel coronary disease with coronary computed tomography angiography based on SYNTAX score II treatment recommendations: design and rationale of the randomised SYNTAX III Revolution trial. EuroIntervention, 2017, 12, 2001-2008.	3.2	28
33	Coronary Artery Bypass Surgery VersusÂDrug-Eluting Stent Implantation forÂLeftÂMain or Multivessel Coronary ArteryÂDisease. JACC: Cardiovascular Interventions, 2016, 9, 2481-2489.	2.9	42
34	Individual Long-Term Mortality PredictionÂFollowing Either Coronary Stenting orÂBypass Surgery in PatientsÂWith Multivessel and/or Unprotected Left MainÂDisease. JACC: Cardiovascular Interventions, 2016, 9, 1564-1572.	2.9	45
35	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. Journal of the American College of Cardiology, 2016, 68, 999-1009.	2.8	95
36	Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease. Journal of the American College of Cardiology, 2016, 68, 29-36.	2.8	52

#	Article	IF	CITATIONS
37	Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. International Journal of Cardiovascular Imaging, 2016, 32, 871-883.	1.5	35
38	Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction. American Journal of Cardiology, 2016, 118 , 17 -22.	1.6	14
39	The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. JACC: Cardiovascular Interventions, 2016, 9, 1231-1242.	2.9	80
40	Tools and Techniques - Clinical: SYNTAX score II calculator. EuroIntervention, 2016, 12, 120-123.	3.2	12
41	Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. EuroIntervention, 2016, 12, e224-e234.	3.2	23
42	Periprocedural myocardial infarction in stent trials: how universal is the third universal definition?. EuroIntervention, 2016, 12, 813-817.	3.2	4
43	Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?. EuroIntervention, 2016, 12, e998-e1008.	3.2	16